Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06305793 · ClinicalTrials.gov registry record · Phase 2

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

A Phase 2 study of Long COVID and Long COVID-19, sponsored by Kanecia Obie Zimmerman.

Active
Registry status
Phase 2
Development phase
200
Enrollment target
1
Study location

NCT06305793 is a Phase 2 study of Long COVID and Long COVID-19 that is active but no longer recruiting, run by Kanecia Obie Zimmerman. The registered enrollment target is 200 participants, below the 2,184-participant average among 50 other Long COVID trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06305793, a Phase 2 study of Long COVID and Long COVID-19, is active but no longer recruiting, sponsored by Kanecia Obie Zimmerman.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in Post-Acute Sequelae of SARS-CoV-2 infection (PASC) participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.

Conditions Studied

Long COVID Long COVID-19 Long Coronavirus Disease 2019 (Covid19)

Interventions

  • BEHAVIORAL Usual Care
  • DRUG IVIG (intravenous immunoglobulin)
  • DRUG IVIG Placebo
  • BEHAVIORAL Coordinated Care

Study Locations (1)

North Carolina

  • All sites listed under NCT06305780 - Durham

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-03-11
Est. Completion 2026-07-01
Phase Phase 2

Sponsor

Kanecia Obie Zimmerman

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06305793

The ClinicalTrials.gov registry entry for NCT06305793 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,184-participant average among 50 other Long COVID trials with a reported enrollment target (91% lower). The listed sponsor is Kanecia Obie Zimmerman, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Long COVID appearing as the primary indexed condition, and to 4 interventions - of which Usual Care is the first listed.

NCT06305793 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06305793 about?

NCT06305793 is a clinical study titled "RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)". This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-ar...

What is the current status of trial NCT06305793?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-03-11. Estimated completion is 2026-07-01.

What conditions does trial NCT06305793 study?

This clinical trial studies the following conditions: Long COVID, Long COVID-19, Long Coronavirus Disease 2019 (Covid19).

What interventions are being tested in trial NCT06305793?

The interventions under investigation include: Usual Care (BEHAVIORAL), IVIG (intravenous immunoglobulin) (DRUG), IVIG Placebo (DRUG), Coordinated Care (BEHAVIORAL).

Who is sponsoring clinical trial NCT06305793?

This trial is sponsored by Kanecia Obie Zimmerman, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06305793 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Long COVID

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Long COVID

All registered trials for this condition

Long COVID-19

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.